Drug Use Research & Management Program
OHA Health Systems Division
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | **Fax** 503-947-1119

Oregon Drug Use Review / Pharmacy & Therapeutics Committee

Thursday, October 6th, 2022 1:00 - 5:00 PM

Via Zoom webinar

MEETING MINUTES

NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 in accordance with Oregon Revised Statute 183.333

Members Present: Bill Origer, MD; Patrick DeMartino, MD; Tim Langford, PharmD; Cat Livingston, MD; Caryn Mickelson, PharmD; Robin Moody, MPH; Eddie Saito, PharmD

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Lan Starkweather, PharmD; Deanna Moretz, PharmD; Sarah Servid, PharmD; Brandon Wells; Kyle Hamilton; Trevor Douglass, DC, MPH; Kathy Sentena, PharmD; Ted Williams, PharmD

Audience: Becky Martin, SK Life Science; Bill McDougall, Biogen; Brandie Feger, Advanced Health CCO; **Brandon Yip, Sanofi**; Car Livingston, Health Share; Chris Tanaka, ViiVhealthcare; Evie Knisely; Fabiola Garcia, Biocodex; Garth Wright, Genentech; Jennifer Shear, Jazz Pharmaceuticals; Jenny Todenhagen, Genentech; **Jessica Chardoulias, Novo Nordisk**; Jim Slater; John Stancil, Artia Solutions; Kailey Skelton, PacificSource Health Plan; **Kaitlin Nguyen, ViiV Healthcare**; Kaitlyn Molina, Samaritan Health Plan; **John Flatt, Marinus**; Kara, Genzyme; Luara Jeffcoat, Abbvie; Lori McDermott, Viking HCS**; Lynda Finch, Biogen**; Mark Kantor, AllCare CCO; Matt Worthy, OHSU; Melissa Bailey-Hall; Michael Foster, BMS; Michele Sabados, Alkermes; Mike Donabedian, Sarepta Therapeutics; Minha Choi, Biogen; Nana Ama Kuffour, IHN; Nguyen Trinh; Paul Thompson, Alkermes; Rick Frees, Vertex Pharmaceuticals; Saghi Maleki, Takeda Pharmaceuticals; **Shirley Quach, Norvartis**; **Sophia Yun, Janssen Scientific Affairs**; **Stuart O'Brochta**, **Gilead**; Sydney Thomas; Teion Turner, UCB Pharma; Terry Lee, Gilead; Tiffany Jones; Tiina Andrews, UHA; Tom Telly; Trish Olson, SK Life Science Inc.; **Troy Whitworth, Neurelis**; Uche Mordi, BMS; YJ Shukla, EOCCO Moda Health; Erin Nowak, Abbvie

(*) Provided verbal testimony
Written testimony: Posted to OSU Website

Drug Use Research & Management Program
OHA Health Systems Division
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | **Fax** 503-947-1119

I. CALL TO ORDER

A. Roll Call & Introductions
- Called to order at approx. 1:02 p.m., introductions by Committee and staff

B. Approval of Agenda - Antiepileptic Drug Class Update with New Drug Evaluation (NDE) pulled off consent agenda to allow for discussion and public comment

C. Conflict of Interest Declaration – no new conflicts of interest were declared

D. Approval of August 2022 Minutes presented by Roger Citron
ACTION: Motion to approve, 2nd, all in favor

E. Department Update provided by Trevor Douglass, DC

II. CONSENT AGENDA TOPICS

A. TIMS DERP Summary
Recommendations:
- No PDL changes recommended based on clinical review
- Modify prior authorization (PA) criteria to reflect updated indications for risankizumab, baricitinib, and ustekinumab
- Evaluate costs in executive session

B. Colony Stimulating Factors Literature Scan
Recommendations:
- No PDL changes recommended based on clinical review
- Evaluate costs in executive session

C. P&T Annual Report
No Public Comment was offered
ACTION: Motion to approve, 2nd, all in favor

III. PREFERRED DRUG LIST NEW BUSINESS

A. Antiepileptic Class Update and NDE: Sara Fletcher, PharmD
Recommendations:
- Designate ganaxolone as voluntary non-preferred and implement safety edit to restrict to FDA approved indication and dose
- Change class name to "Outpatient Antiepileptics" and include new autoinjector formulation of midazolam as non-preferred
- No other PDL changes recommended based on clinical information
- Evaluate costs in executive session

Public Comment: John Flatt, Marinus; Troy Whitworth, Neurelis
ACTION: Motion to approve, 2nd, all in favor

Drug Use Research & Management Program
OHA Health Systems Division
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | **Fax** 503-947-1119

B. Multiple Sclerosis Class Update with NDE: Deanna Moretz, PharmD
Recommendations:
- No PDL changes recommended based on clinical review
- Consolidate injectable MS criteria as presented
- Evaluate costs in executive session
Public Comment: Shirley Quach, Novartis; Lynda Finch, Biogen; Sophia Yun, Janssen
ACTION: The Committee recommended amending the oral MS PA criteria to remove required step therapy
Motion to approve, 2nd, all in favor

C. Human Immunodeficiency Virus (HIV) Lit Scan: Sara Fletcher, PharmD
Recommendations:
-Designate stavudine, didanosine, saquinavir, and nelfinavir as non-preferred on the PDL
Public Comment: Kaitlin Nguyen, ViiV Healthcare; Stuart O'Brochta, Gilead
ACTION: Motion to approve, 2nd, all in favor

D. GLP-1 Receptor Agonists & SGLT-2 Inhibitors Drug Class Updates with NDE:
Kathy Sentena, PharmD
Recommendations:
- Include the glucose-dependent insulinotropic polypeptide (GIP) therapies in the PA criteria with GLP-1 RAs
- Update the GLP-1 RA PA criteria to remove concomitant prandial insulin restriction
- Maintain SGLT2 inhibitors PA criteria and require renal function evaluation annually
- Maintain tirzepatide as non-preferred on the preferred drug list (PDL) and subject to the GLP-1 RA and GLP + GIP agonist PA criteria
- Evaluate costs in executive session
Public Comment: Jessica Chardoulias, Novo Nordisk
ACTION: Motion to approve, 2nd, all in favor

E. Dupixent® (dupilumab) PA Criteria Update: Deanna Moretz, PharmD
Recommendations:
- Update clinical prior authorization (PA) criteria to: Approve treatment of eosinophilic esophagitis in patients aged 12 years of age and older who weigh at least 40 kg
- Allow appropriate step therapy for PPIs in patients with eosinophilic esophagitis
- Approve treatment of moderate-to-severe atopic dermatitis in patients not adequately controlled with topical therapies, or in patients 6 months or older when topical therapies are not advisable
Public Comment: Brandon Yip, Sanofi
ACTION: Motion to approve, 2nd, all in favor

Drug Use Research & Management Program
OHA Health Systems Division
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | **Fax** 503-947-1119

IV. DUR NEW BUSINESS

A. Attention-Deficit/Hyperactivity Disorder (ADHD) Literature Scan and DUE:
Dave Engen, PharmD**;** Sarah Servid, PharmD
Recommendations:
- No PDL changes recommended based on clinical review
- Revise PA criteria to reflect maximum age and dose limits as specified in product labeling or supported compendia
- Exclude patients initiated on an ADHD medication as a child from PA if they exceed maximum age limit
-Evaluate costs in executive session
Motion to approve, 2nd, all in favor

B. Lumateperone Drug Use Evaluation: Ted Williams, PharmD
Recommendations:
- Consider outreach to providers and regions with higher use of lumateperone to identify reasons for practice differences
- Consider provider education programs to raise awareness of the similar outcomes and higher costs associated with lumateperone
- No changes to utilization controls for lumateperone are warranted at this time
Motion to approve, 2nd, all in favor

C. Annovera® (ethinyl estradiol/segesterone) PA Update: Sara Fletcher, PharmD
Recommendations:
- Implement 300-day minimum supply for POS prescriptions
- Require POS override for 1st refill if less than 300 days from previous prescription fill
- Implement quantity limit for 2nd refill within 12-months
Motion to approve, 2nd, all in favor

V. EXECUTIVE SESSION

Members Present: Bill Origer, MD; Patrick DeMartino, MD; Tim Langford, PharmD; Cat Livingston, MD; Caryn Mickelson, PharmD; Eddie Saito, PharmD

Staff Present: Roger Citron, RPh; David Engen, PharmD; Sara Fletcher, PharmD; Lan Starkweather, PharmD; Deanna Moretz, PharmD; Sarah Servid, PharmD; Brandon Wells; Kyle Hamilton; Trevor Douglass, DC, MPH; Kathy Sentena, PharmD;

Drug Use Research & Management Program
OHA Health Systems Division
500 Summer Street NE, E35; Salem, OR 97301-1079
Phone 503-947-5220 | **Fax** 503-947-1119

VI. RECONVENE for PUBLIC RECOMMENDATIONS

A. **TIMS DERP Summary**
Recommendation: No changes to the PDL are recommended
ACTION: Motion to approve, 2nd, all in favor

B. **Colony Stimulating Factors Literature Scan**
Recommendation: Make Granix (tbo-filgrastim) non-preferred on the PDL
ACTION: Motion to approve, 2nd, all in favor

C. **Antiepileptic Class Update and NDE:**
Recommendation: Make Nayzilam (midazolam spray) and Valtoco (diazepam spray) preferred on the PDL
ACTION: Motion to approve, 2nd, all in favor

D. **Multiple Sclerosis Class Update with NDE:**
Recommendation: Make peginterferon (Plegridy) preferred on the PDL
ACTION: Motion to approve, 2nd, all in favor

E. **GLP-1 Receptor Agonists & SGLT-2 Inhibitors Drug Class Updates with NDE**
Recommendation: No changes to the PDL are recommended
ACTION: Motion to approve, 2nd, all in favor

F. **ADHD Literature Scan & DUE**
Recommendation: Make Qelbree® (viloxazine) preferred on the PDL
ACTION: Motion to approve, 2nd, all in favor

VII. ADJOURN